The Patent Finder

Hanmi Pharm. Co., Ltd.

96 patents currently held · Updated Nov 15, 2026
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 8 name spellings.

1
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 6 to 8, 2027 · next Feb 6
  • 3 fees due Mar 3 to 12, 2027 · next Mar 3
  • 2 fees due Apr 8 to 15, 2027 · next Apr 8
  • 1 fee due May 26, 2027
    The maintenance fee for Conjugate of Biologically Active Polypeptide Monomer and Immunoglobulin FC Fragment with Reduced Receptor-Mediated Clearance, and the Method for Preparing the Same (US 10,487,128) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 4 fees due Jun 3 to 30, 2027 · next Jun 3
  • 1 fee due Aug 4, 2027
    The maintenance fee for Composition for treating diabetes or diabesity comprising oxyntomodulin analog (US 10,550,168) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 2 fees due Sep 12 to 15, 2027 · next Sep 12
  • 1 fee due Nov 12, 2027
    The maintenance fee for Insulin Analogs and Use Thereof (US 10,647,753) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 8 of the patents on this record were granted since Aug 17, 2026
  • 2 terms have ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US D700,315Pharmaceutical tablet
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,731,022Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,931,406Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,220,704Composite formulation comprising a tablet encapsulated in a hard capsule
In force
 · From the USPTO record
In forceFrom the USPTO record
US RE47,451Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,504,757Site-Specific GLP-2 Conjugate Using an Immunoglobulin Fragment
In force
 · High confidence
In forceHigh confidence
US 9,394,560Method of culturing E. coli cells for high density
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,801,950Liquid formulation of long acting insulinotropic peptide conjugate
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,833,516Liquid formulation of long-acting insulin and insulinotropic peptide
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,901,621Composition for Treating Hyperlipidemia Comprising Oxyntomodulin Derivative
In force
 · Medium confidence
In forceMedium confidence
10 of 96 patents shown.
Pro members see all 96.
Pro members: see all 96 patents
Also on record, not counted in the 96: 10 patents in force now held by others · 61 lapsed for an unpaid fee · 19 ended at full term · 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

44 pending · 16 abandoned · 75 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited